Spyre Therapeutics, Inc. (SYRE)

NASDAQ: SYRE · IEX Real-Time Price · USD

35.58

+1.27 (3.70%)

At close: Apr 18, 2024, 4:00 PM

34.87

-0.71 (-2.00%)

After-hours: Apr 18, 2024, 4:06 PM EDT

Spyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	0.89	2.33	18.74	0	0	3.89	5.21	4.63	6.09	0
Revenue Growth (YoY)	-61.96%	-87.57%	-	-	-	-25.30%	12.47%	-23.94%	-	-
Gross Profit	0.89	2.33	18.74	0	0	3.89	5.21	4.63	6.09	0
Selling, General & Admin	39.95	28.53	27.32	21.84	15.73	12.63	10.07	8.39	5.95	2.07
Research & Development	89.5	58.58	57.07	59.64	64.6	36.72	22.82	18.14	11.45	6.83
Other Operating Expenses	113.74	0	0	0	0	0	0	0	0	0
Operating Expenses	243.19	87.11	84.39	81.48	80.33	49.35	32.88	26.53	17.4	8.9
Operating Income	-242.3	-84.78	-65.65	-81.48	-80.33	-45.46	-27.68	-21.91	-11.32	-8.9
Other Expense / Income	96.51	-0.83	0.01	-0.59	-2.08	-1.12	-0.44	-0.21	-0.02	1.44
Pretax Income	-338.82	-83.95	-65.66	-80.89	-78.25	-44.35	-27.24	-21.7	-11.3	-10.35
Income Tax	-0.03	-0.14	0.14	0	0	0	0	0	0	0
Net Income	-338.79	-83.82	-65.8	-80.89	-78.25	-44.35	-27.24	-21.7	-11.3	-10.35
Preferred Dividends	0	0	0	0	0	0	0	0	0.23	0
Net Income Common	-338.79	-83.82	-65.8	-80.89	-78.25	-44.35	-27.24	-21.7	-11.52	-10.35
Shares Outstanding (Basic)	7	3	3	2	1	1	1	0	0	0
Shares Outstanding (Diluted)	7	3	3	2	1	1	1	0	0	0
Shares Change	104.59%	28.19%	23.18%	67.05%	53.44%	37.64%	54.50%	1532.50%	263.52%	-
EPS (Basic)	-49.12	-24.86	-25.02	-38.00	-61.25	-53.25	-45.00	-55.50	-480.25	-
EPS (Diluted)	-49.12	-24.86	-25.02	-38.00	-61.25	-53.25	-45.00	-55.50	-480.25	-
Free Cash Flow	-99.44	-80.18	-54.29	-80.06	-67.18	-32.62	-25.23	-19.05	-11.19	-7.52
Free Cash Flow Per Share	-14.42	-23.78	-20.64	-37.50	-52.57	-39.16	-41.70	-48.64	-466.42	-1138.79
Gross Margin	100.00%	100.00%	100.00%	-	-	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-27347.97%	-3640.23%	-350.33%	-	-	-1169.32%	-531.72%	-473.34%	-185.95%	-
Profit Margin	-38238.15%	-3598.75%	-351.14%	-	-	-1140.64%	-523.27%	-468.84%	-189.37%	-
Free Cash Flow Margin	-11222.91%	-3442.77%	-289.71%	-	-	-838.86%	-484.80%	-411.67%	-183.89%	-
EBITDA	-337.85	-81.99	-63.66	-79.27	-77.35	-44.06	-26.99	-21.57	-11.21	-10.33
EBITDA Margin	-38132.28%	-3520.27%	-339.71%	-	-	-1133.10%	-518.48%	-465.99%	-184.16%	-
Depreciation & Amortization	0.96	1.96	2	1.62	0.9	0.29	0.25	0.13	0.09	0.02
EBIT	-338.82	-83.95	-65.66	-80.89	-78.25	-44.35	-27.24	-21.7	-11.3	-10.35
EBIT Margin	-38241.08%	-3604.59%	-350.39%	-	-	-1140.64%	-523.27%	-468.84%	-185.62%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).